We believe our operations focus, coupled with our team’s background and experience, will make us an attractive partner for high-quality businesses with exceptional management teams.

Our Team

Our team has extensive life science industry expertise, network, and track record of successful deal execution.

James R. Neal has more than twenty years of experience in the biotechnology industry encompassing roles in research and development (R&D), business development, financing and general management. Mr. Neal currently serves as Chief Executive Officer and member of the board of XOMA (Nasdaq: XOMA). He joined XOMA in 2009 and was appointed to the Chief Executive Officer role in late 2016. In early 2017, Mr. Neal led XOMA through a dramatic strategic pivot taking the company from a traditional R&D heavy biotech company and transforming it to a successful royalty monetization and aggregation company.

In the years prior to becoming Chief Executive Officer of XOMA, he was instrumental in leading the company’s licensing and business development activities focused on maximizing the value of XOMA’s foundational antibody IP and knowhow.

In addition to his role at XOMA, Mr. Neal currently serves as Chairman of the board of directors of Palisade Bio, Inc. (Nasdaq: PALI), a clinical-stage biopharmaceutical company, following the merger of Leading Biosciences, Inc. and Seneca Biopharma, Inc. in April 2021. Prior to XOMA, Mr. Neal was Acting Chief Executive Officer of Entelos, Inc., a leading bio-simulation company that acquired Iconix Biosciences, a privately held company where Mr. Neal also served as Chief Executive Officer. At Iconix, Mr. Neal established multi-year collaborations with Bristol-Myers Squibb, Abbott Labs (now AbbVie), Eli Lilly and the U.S. Food and Drug Administration.

From 1999 to 2002, he was Executive Vice President of Incyte Genomics, leading global commercial activities with pharmaceutical company collaborators and partners including Pfizer, GSK and others. Earlier in his career, he was an executive with Monsanto Company in positions of increasing responsibility. Mr. Neal earned his B.Sc. in Agriculture and his M.Sc. in Genetics and Plant Breeding, each from the University of Manitoba, Canada, and holds an MBA degree from Washington University in St. Louis, MO.

Jim Neal

Frances K. Heller has over 25 years of experience in the pharmaceutical and biotech industries in business development, licensing and legal affairs. Ms. Heller is the Founder, and has served as the Chief Executive Officer and Chair of Good2Go, Inc., an IoT technology company, since its formation in 2015.

She also serves on the board of Affinivax, Inc. a private early-stage vaccine company and co-chairs the LavaMaeˣ board, a nonprofit that teaches people around the world to bring mobile showers and other services that promote well-being to people experiencing homelessness.

Previously she was Senior Vice President of business development at Bristol-Myers Squibb, a Trustee of the Bristol-Myers Squibb Foundation, a Trustee at Dana Farber Cancer Institute, and an adviser to GoFundMe’s Impact Fund. Prior to joining Bristol-Myers Squibb, Ms. Heller was Executive Vice President of business development at Exelixis Pharmaceuticals and prior to joining Exelixis, Ms. Heller was head of strategic alliances at Novartis Pharmaceuticals.

Ms. Heller is a member of the California State Bar and licensed by the U.S. Patent and Trademark Office. She holds a B.S. in biology from Tulane University, an M.A. in biology from American University and a J.D. from Golden Gate University School of Law.

Fran Heller

Jonas Grossman has served as Managing Partner and Head of Capital Markets for Chardan since December 2003, and has additionally served as President of Chardan since September 2015. With nearly two decades of transactional and special purpose acquisition company expertise, Mr. Grossman has led or managed more than 500 transactions, including providing underwriting and business combination advisory services to more than 85 special purpose acquisition companies in a variety of industries.

Mr. Grossman has been a founder and/or a member of the board of seven special purpose acquisition companies, of which on four he also has served as Chief Executive Officer and President. Since April 2020, Mr. Grossman has served as the President and Chief Executive Officer of Chardan Healthcare Acquisition 2 Corp which announced its merger with Renovacor, Inc in March 2021. He also served as President and Chief Executive Officer of Chardan Healthcare Acquisition Corp. from March 2018 until its merger in October 2019 with BiomX Ltd. (NYSE: PHGE).

He is currently a director of BiomX. Mr. Grossman also serves as the President and Chief Executive Officer of Chardan NexTech Acquisition Corp. and Chardan NexTech Acquisition 2 Corp., each, a special purpose acquisition company. Mr. Grossman was a founder and director of LifeSci Acquisition Corp. from March 2020 until the close of its business combination with Vincera Pharma, Inc. in December 2020. He has served as a director to Ventoux CCM Acquisition Corp. since December 2020 and CleanTech Acquisition Corp since July 2021. Previously, from 2001 to 2003, Mr. Grossman worked at Ramius Capital Group, LLC, a global multi-strategy hedge fund where he served as Vice President and Head Trader. Mr. Grossman holds a B.A. in Economics from Cornell University and an M.B.A. from New York University’s Stern School of Business. He has served on the board of directors for UNICEF since December 2016.

Jonas Grossman

Sandip I. Patel, Esq. has been involved in the formation, acquisition, development, growth, and liquidity events related to companies in the healthcare, insurance and financial services fields. Mr. Patel currently holds public and private investments in a wide range of industries with a focus on medical devices, biotechnology, healthcare services and related technologies, as well as FinTech and related services.

He currently serves as a director for Quantum FinTech Acquisition Corporation, a special purpose acquisition company focused on financial technology. Mr. Patel is also a co-founding shareholder of AtlasBanc, and was a co-founding shareholder, and board member of Anderen Bank. He served on the board of directors for Avatar Property and Casualty Insurance Company, a Florida-based homeowners insurance company.

Mr. Patel was the Founder, President and Chief Executive Officer of the Orion group of companies, a full-service real estate development company concentrating on high end waterfront multi-family and commercial developments with a number of successful projects developed in the Tampa Bay area. Previously, Mr. Patel served as Head of the New Business Development and Mergers and Acquisitions (“M&A”) team to national health insurance companies. Mr. Patel oversaw all legal, regulatory and governmental affairs on behalf of the WellCare group of companies which included, WellCare HMO of Florida, WellCare of New York, WellCare of Connecticut, StayWell and HealthEase HMO (“WellCare”), while serving as its General Counsel and as a partner in the company. Mr. Patel successfully negotiated the sale of a majority of WellCare to a large private equity fund. Mr. Patel received his JD degree from the Stetson University College of Law, and a B.B.A. in Finance from the University of Georgia.

Sandip Patel

William McKeever has served as our Chief Financial Officer since May 2021. Mr. McKeever has more than 20 years of experience in the healthcare industry encompassing various roles in equity research, portfolio management and investment banking.

Since 2017, Mr. McKeever has worked as a consultant to various companies that are creating breakthrough technologies to treat diseases in the healthcare industry. From 2010 to 2016, Mr. McKeever was Managing Director of First Bridgehouse Securities, a boutique investment firm.

Prior to that, Mr. McKeever was a sell-side equity analyst covering the managed care industry at firms including PaineWebber from 1997 to 2000 and UBS from 2000 to 2005. While at PaineWebber and UBS, he was a managing director and was ranked for several year as an All-American Analyst by Institutional Investor magazine based on its poll of analysts around the country. While at UBS, he was involved in several initial public offerings of managed care companies.

From 2005 to 2009, Mr. McKeever was a Managing Director managing all health care investments including pharmaceuticals, medical devices, services and biotechnology in the Principal Credit Group (PCG) of Merrill Lynch. PCG was an internal fund that managed debt and equity investments in all sectors globally. Mr. McKeever earned his B.A. in Economics from Denison University and his M.B.A. in Finance from the Wharton School of the University of Pennsylvania.

William McKeever
CFO, Director

Sanjeev Satyal, Ph.D. has served as our Chief Executive Officer since April 2021. From 2015 to February 2021, he also served as Vice President of Research & Development at pH Pharma.

Previously, Sanjeev served as Vice President, Biology at StemGuard Therapeutics, as a Director of Research at StemPar Sciences and as a Director of Cancer Biology at OncoMed Pharmaceuticals. Sanjeev was a postdoctoral fellow at Genentech. Sanjeev is the inventor of over 30 U.S. issued or pending patents, and their foreign counterparts, in various pharmaceutical areas and has co-authored several scientific publications.

Sanjeev earned a B.Sc. in Life Sciences at St. Xavier’s College, University of Bombay, an M.Sc. in Biotechnology at the University of Poona and a Ph.D. in Biochemistry at Northwestern University.

Sanjeev Satyal

Let's Work Together

If you’re interested in learning more about our company, please reach out.